Ashfords advised life sciences company Iksuda Therapeutics on the deal. Bird & Bird advised Mirae Asset Capital, Celltrion and Premier Partners.Iksuda is the developer of a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
